Abstract: An example transmission comprising a lubricant feed passageway to receive lubricant; an input shaft having a cavity that defines a shaft collection trough to receive the lubricant from the lubricant feed passageway, the input shaft defining a radial passageway to enable the lubricant to flow from the shaft collection trough to an exterior surface of the input shaft; and a carrier to receive at least a portion of the input shaft, the carrier defining a carrier collection trough and channels formed in the carrier to distribute the lubricant to at least one of rotating components or non-rotating components in the carrier, the carrier collection trough to receive the lubricant from the shaft collection trough via the radial passageway in response to the input shaft rotating.

Abstract: The present invention is directed to methods of inhibiting or preventing photophobia in subjects in need thereof using anti-CGRP antibodies or antibody fragments that inhibit photophobia, especially CGRP-associated photophobia. These antibodies and fragments are useful in treating different disorders associated with photophobia such as migraine, cluster headaches and the like. The present invention also provides assays using transgenic Nestin/Ramp1 rodents, utilizing a CGRP model light aversive behavior model for identifying therapeutically effective anti-CGRP antibodies and fragments thereof having binding specificity for CGRP which inhibit or prevent photophobia in subjects in need thereof. The present invention is specifically directed to methods for identifying therapeutically effective antibodies and fragments thereof having binding specificity for CGRP that may be used to treat CGRP associated disorders such as migraine.

Abstract: The present invention is directed to methods for treating diarrhea, both chronic or acute forms, by the administration of a therapeutically or prophylactically effective amount of antibodies and fragments thereof having binding specificity for CGRP. In particular the methods prevent or reduce diarrhea in conditions or treatments resulting in elevated CGRP levels, e.g., in the GI tract (colon) that are associated with diarrhea and/or improper electrolyte and fluid excretion from the bowel or urinary system. More specifically, this invention relates to treatments using the anti-CGRP antibodies and fragments described herein, and binding fragments thereof.

Abstract: The present invention is directed to methods for treating diarrhea, both chronic or acute forms, by the administration of a therapeutically or prophylactically effective amount of antibodies and fragments thereof having binding specificity for CGRP. In particular the methods prevent or reduce diarrhea in conditions or treatments resulting in elevated CGRP levels, e.g., in the GI tract (colon) that are associated with diarrhea and/or improper electrolyte and fluid excretion from the bowel or urinary system. More specifically, this invention relates to treatments using the anti-CGRP antibodies and fragments described herein, and binding fragments thereof.

Abstract: The present invention is directed to methods of inhibiting or preventing photophobia in subjects in need thereof using anti-CGRP antibodies or antibody fragments that inhibit photophobia, especially CGRP-associated photophobia. These antibodies and fragments are useful in treating different disorders associated with photophobia such as migraine, cluster headaches and the like. The present invention also provides assays using transgenic Nestin/Ramp1 rodents, utilizing a CGRP model light aversive behavior model for identifying therapeutically effective anti-CGRP antibodies and fragments thereof having binding specificity for CGRP which inhibit or prevent photophobia in subjects in need thereof. The present invention is specifically directed to methods for identifying therapeutically effective antibodies and fragments thereof having binding specificity for CGRP that may be used to treat CGRP associated disorders such as migraine.

Abstract: The present invention is directed to methods for treating diarrhea, both chronic or acute forms, by the administration of a therapeutically or prophylactically effective amount of antibodies and fragments thereof having binding specificity for CGRP. In particular the methods prevent or reduce diarrhea in conditions or treatments resulting in elevated CGRP levels, e.g., in the GI tract (colon) that are associated with diarrhea and/or improper electrolyte and fluid excretion from the bowel or urinary system. More specifically, this invention relates to treatments using the anti-CGRP antibodies and fragments described herein, and binding fragments thereof.

Abstract: The present invention is directed to methods of inhibiting or preventing photophobia in subjects in need thereof using anti-CGRP antibodies or antibody fragments that inhibit photophobia, especially CGRP-associated photophobia. These antibodies and fragments are useful in treating different disorders associated with photophobia such as migraine, cluster headaches and the like. The present invention also provides assays using transgenic Nestin/Ramp1 rodents, utilizing a CGRP model light aversive behavior model for identifying therapeutically effective anti-CGRP antibodies and fragments thereof having binding specificity for CGRP which inhibit or prevent photophobia in subjects in need thereof. The present invention is specifically directed to methods for identifying therapeutically effective antibodies and fragments thereof having binding specificity for CGRP that may be used to treat CGRP associated disorders such as migraine.

Abstract: The present invention is directed to methods for treating diarrhea, both chronic or acute forms, by the administration of a therapeutically or prophylactically effective amount of antibodies and fragments thereof having binding specificity for CGRP. In particular the methods prevent or reduce diarrhea in conditions or treatments resulting in elevated CGRP levels, e.g., in the GI tract (colon) that are associated with diarrhea and/or improper electrolyte and fluid excretion from the bowel or urinary system. More specifically, this invention relates to treatments using the anti-CGRP antibodies and fragments described herein, and binding fragments thereof.

Abstract: A transmission includes a first pericyclic motion converter having a first aperture to receive at least a portion of an output shaft and a second pericyclic motion converter having a second aperture to receive at least a portion of the output shaft. A first bearing is positioned between an inner surface of the first pericyclic motion converter defined by the first aperture and an outer surface of the output shaft. A second bearing is positioned between an inner surface of the second pericyclic motion converter defined by the second aperture and the outer surface of the output shaft.

Abstract: The present invention is directed to methods for treating diarrhea, both chronic or acute forms, by the administration of a therapeutically or prophylactically effective amount of antibodies and fragments thereof having binding specificity for CGRP. In particular the methods prevent or reduce diarrhea in conditions or treatments resulting in elevated CGRP levels, e.g., in the GI tract (colon) that are associated with diarrhea and/or improper electrolyte and fluid excretion from the bowel or urinary system. More specifically, this invention relates to treatments using the anti-CGRP antibodies and fragments described herein, and binding fragments thereof.

Abstract: The present invention is directed to methods of inhibiting or preventing photophobia in subjects in need thereof using anti-CGRP antibodies or antibody fragments that inhibit photophobia, especially CGRP-associated photophobia. These antibodies and fragments are useful in treating different disorders associated with photophobia such as migraine, cluster headaches and the like. The present invention also provides assays using transgenic Nestin/Ramp1 rodents, utilizing a CGRP model light aversive behavior model for identifying therapeutically effective anti-CGRP antibodies and fragments thereof having binding specificity for CGRP which inhibit or prevent photophobia in subjects in need thereof. The present invention is specifically directed to methods for identifying therapeutically effective antibodies and fragments thereof having binding specificity for CGRP that may be used to treat CGRP associated disorders such as migraine.

Abstract: An example transmission includes a first pericyclic motion converter to wobble at an angle relative to a first reaction control member and a first output shaft gear. The first pericyclic motion converter having gear teeth to engage a portion of gear teeth at a circumference of the first reaction control member to provide a first gear mesh and to engage a portion of gear teeth at a circumference of the first output shaft gear to provide a second gear mesh. A second pericyclic motion converter wobbles at an angle relative to a second reaction control member and a second output shaft gear. The second pericyclic motion converter having gear teeth to engage a portion of gear teeth at a circumference of the second reaction control member to provide a third gear mesh and engage a portion of gear teeth at a circumference of the second output shaft gear to provide a fourth gear mesh.

Abstract: The present invention is directed to methods of inhibiting or preventing photophobia in subjects in need thereof using anti-CGRP antibodies or antibody fragments that inhibit photophobia, especially CGRP-associated photophobia. These antibodies and fragments are useful in treating different disorders associated with photophobia such as migraine, cluster headaches and the like.

Abstract: Power transmissions are disclosed. An example transmission includes a first pericyclic motion converter having a first aperture to receive at least a portion of an output shaft and a second pericyclic motion converter having a second aperture to receive at least a portion of the output shaft. A first bearing is positioned between an inner surface of the first pericyclic motion converter defined by the first aperture and an outer surface of the output shaft. A second bearing is positioned between an inner surface of the second pericyclic motion converter defined by the second aperture and the outer surface of the output shaft.

Abstract: Power transmissions are disclosed. An example transmission includes a first pericyclic motion converter to wobble at an angle relative to a first reaction control member and a first output shaft gear. The first pericyclic motion converter having gear teeth to engage a portion of gear teeth at a circumference of the first reaction control member to provide a first gear mesh and to engage a portion of gear teeth at a circumference of the first output shaft gear to provide a second gear mesh. A second pericyclic motion converter wobbles at an angle relative to a second reaction control member and a second output shaft gear. The second pericyclic motion converter having gear teeth to engage a portion of gear teeth at a circumference of the second reaction control member to provide a third gear mesh and engage a portion of gear teeth at a circumference of the second output shaft gear to provide a fourth gear mesh.

Abstract: The disclosed embodiments include methods and systems that automatically populate interfaces facilitating electronic transactions. In one embodiment, a system may detect an action of a first user that triggers an account transfer transaction. The system may also determine a first account associated with the first user based on the detected action, and determine a second account based on the detected action and a set of rules associated with the first user. The system may generate, based on the detected event and the set of rules, first information used to provide prefilled content identifying the first account as a source account and the determined second account as a destination account. The system may also generate, in response to an authorization, second information used to provide second content including a notification that a transfer of funds from the first account to the second account has occurred.

Abstract: The disclosed embodiments include methods and systems that automatically populate interfaces facilitating electronic transactions. In one embodiment, a system may identify a contextual event triggering an account transfer transaction. The system may also determine a first account associated with a first user based on the contextual event, and determine a second account based on the contextual event and a set of rules associated with the first user. The system may generate, based on the detected event and the set of rules, first information used to provide prefilled content identifying the first account as a source account and the determined second account as a destination account. The system may also generate, in response to an authorization, second information used to provide second content including a notification that a transfer of funds from the first account to the second account has occurred.

Abstract: The disclosed embodiments include methods and systems that automatically populate interfaces facilitating electronic transactions. In one embodiment, a system may detect an system-generated event triggering an account transfer transaction. The system may also determine a first account associated with a first user based on the detected event, and determine a second account based on the detected event and a set of rules associated with the first user. The system may generate, based on the detected event and the set of rules, first information used to provide prefilled content identifying the first account as a source account and the determined second account as a destination account. The system may also generate, in response to an authorization, second information used to provide second content including a notification that a transfer of funds from the first account to the second account has occurred.

Abstract: Systems, devices, methods, and compositions that improve the scent perception for a user. Improved scent perception is achieved by presenting alternating scents and by varying levels of output of scents, as well as by minimizing device clogging, thereby improving evaporation profiles.

Abstract: Air freshener products and methods for freshening air are disclosed. In some embodiments, the air freshening product may include a container for storing an air freshening composition that may contain compressed gas such as compressed air, nitrogen, nitrous oxide, inert gases, or carbon dioxide. When the container is completely filled with propellant and air freshening composition, the air freshening composition may be released from the container at a flow rate of from about 0.8 grams/second to about 1.5 grams/second, wherein the mean particle size of the released spray droplets is from about 10 microns to about 100 microns. The method of freshening air, in certain embodiments, provides improved delivery of an air freshening composition using a non-hydrocarbon propellant. If malodor counteractants are used, the method may also provide a reduction in malodors.